File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1097/FJC.0b013e3182073e27
- Scopus: eid_2-s2.0-84855358922
- PMID: 21283024
- WOS: WOS:000298669500003
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Nebivolol: An endothelium-friendly selective β 1- adrenoceptor blocker
Title | Nebivolol: An endothelium-friendly selective β 1- adrenoceptor blocker | ||||||
---|---|---|---|---|---|---|---|
Authors | |||||||
Keywords | β-blocker chronic heart failure hypertension nitric oxide reactive oxygen species | ||||||
Issue Date | 2012 | ||||||
Publisher | Lippincott Williams & Wilkins. The Journal's web site is located at http://www.cardiovascularpharm.com/ | ||||||
Citation | Journal Of Cardiovascular Pharmacology, 2012, v. 59 n. 1, p. 16-21 How to Cite? | ||||||
Abstract | Nebivolol is a highly selective β 1-adrenoceptor blocker, which also stimulates endothelial nitric oxide synthase and scavenges reactive oxygen species (ROS). These characteristics endow nebivolol, compared with conventional β-blockers, with a favorable hemodynamic profile for the treatment of hypertension, chronic heart failure, and possibly other cardiovascular diseases. Nebivolol is a racemic mixture of d- and l-isomers. Its β 1-antagonistic properties reside primarily with d-nebivolol although both isomers are capable of increasing the release of NO from the endothelium after binding to β 2- or β 3- adrenergic receptors. The latter action results in vasodilatation and reduced vascular resistance. Nebivolol also scavenges ROS in a receptor-independent manner by direct interaction with free radicals. By scavenging ROS nebivolol not only reduces oxidant stress but also augments NO bioavailability. The endothelial nitric oxide synthase -stimulating and ROS scavenging effects of nebivolol act synergistically to provide cardiovascular protection in addition to its β 1-antagonistic action. © 2012 Lippincott Williams & Wilkins, Inc. | ||||||
Persistent Identifier | http://hdl.handle.net/10722/146890 | ||||||
ISSN | 2023 Impact Factor: 2.6 2023 SCImago Journal Rankings: 0.610 | ||||||
ISI Accession Number ID |
Funding Information: Supported in part by the National Natural Science Foundation of China Grant No. 30770789 and 30870938 and by the Hong Kong Research Grant Council (University of Hong Kong-777507M). | ||||||
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Gao, Y | en_HK |
dc.contributor.author | Vanhoutte, PM | en_HK |
dc.date.accessioned | 2012-05-23T05:48:50Z | - |
dc.date.available | 2012-05-23T05:48:50Z | - |
dc.date.issued | 2012 | en_HK |
dc.identifier.citation | Journal Of Cardiovascular Pharmacology, 2012, v. 59 n. 1, p. 16-21 | en_HK |
dc.identifier.issn | 0160-2446 | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/146890 | - |
dc.description.abstract | Nebivolol is a highly selective β 1-adrenoceptor blocker, which also stimulates endothelial nitric oxide synthase and scavenges reactive oxygen species (ROS). These characteristics endow nebivolol, compared with conventional β-blockers, with a favorable hemodynamic profile for the treatment of hypertension, chronic heart failure, and possibly other cardiovascular diseases. Nebivolol is a racemic mixture of d- and l-isomers. Its β 1-antagonistic properties reside primarily with d-nebivolol although both isomers are capable of increasing the release of NO from the endothelium after binding to β 2- or β 3- adrenergic receptors. The latter action results in vasodilatation and reduced vascular resistance. Nebivolol also scavenges ROS in a receptor-independent manner by direct interaction with free radicals. By scavenging ROS nebivolol not only reduces oxidant stress but also augments NO bioavailability. The endothelial nitric oxide synthase -stimulating and ROS scavenging effects of nebivolol act synergistically to provide cardiovascular protection in addition to its β 1-antagonistic action. © 2012 Lippincott Williams & Wilkins, Inc. | en_HK |
dc.language | eng | en_US |
dc.publisher | Lippincott Williams & Wilkins. The Journal's web site is located at http://www.cardiovascularpharm.com/ | en_HK |
dc.relation.ispartof | Journal of Cardiovascular Pharmacology | en_HK |
dc.subject | β-blocker | en_HK |
dc.subject | chronic heart failure | en_HK |
dc.subject | hypertension | en_HK |
dc.subject | nitric oxide | en_HK |
dc.subject | reactive oxygen species | en_HK |
dc.subject.mesh | Adrenergic beta-1 Receptor Antagonists - administration and dosage - pharmacology - therapeutic use | - |
dc.subject.mesh | Benzopyrans - administration and dosage - pharmacology - therapeutic use | - |
dc.subject.mesh | Endothelium, Vascular - drug effects - enzymology - metabolism | - |
dc.subject.mesh | Ethanolamines - administration and dosage - pharmacology - therapeutic use | - |
dc.subject.mesh | Heart Failure - drug therapy - metabolism | - |
dc.title | Nebivolol: An endothelium-friendly selective β 1- adrenoceptor blocker | en_HK |
dc.type | Article | en_HK |
dc.identifier.email | Vanhoutte, PM: vanhoutt@hku.hk | en_HK |
dc.identifier.authority | Vanhoutte, PM=rp00238 | en_HK |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1097/FJC.0b013e3182073e27 | en_HK |
dc.identifier.pmid | 21283024 | - |
dc.identifier.scopus | eid_2-s2.0-84855358922 | en_HK |
dc.identifier.hkuros | 199412 | en_US |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-84855358922&selection=ref&src=s&origin=recordpage | en_HK |
dc.identifier.volume | 59 | en_HK |
dc.identifier.issue | 1 | en_HK |
dc.identifier.spage | 16 | en_HK |
dc.identifier.epage | 21 | en_HK |
dc.identifier.isi | WOS:000298669500003 | - |
dc.publisher.place | United States | en_HK |
dc.identifier.scopusauthorid | Gao, Y=36865936300 | en_HK |
dc.identifier.scopusauthorid | Vanhoutte, PM=7202304247 | en_HK |
dc.identifier.issnl | 0160-2446 | - |